Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-178-2 | CAS number: 7789-60-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- reproductive toxicity, other
- Remarks:
- Subacute
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Justification for type of information:
- Data is from secondary source
Data source
Reference
- Reference Type:
- other: NTRL
- Title:
- Acute and Subchronic Toxicity Evaluations of the Halon Replacement Candidate Phosphorus Tribromide.
- Author:
- Robin E. Wolfe,Marcia L. Feldmann,David H. Ellis,Harry F. Leahy,arlyle D. Flemming,Darol E. Dodd
- Year:
- 1 997
- Bibliographic source:
- Armstrong Laboratory, Occupational and Environmental Health Directorate Toxicology Division, Human Systems Center Air Force Materiel Command,Wright-Patterson, 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: No data
- Principles of method if other than guideline:
- Subacute repeated dsoe inhalation toxicity study of phosphorus (3+) tribromide in male rat
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Phosphorus tribromide
- EC Number:
- 232-178-2
- EC Name:
- Phosphorus tribromide
- Cas Number:
- 7789-60-8
- Molecular formula:
- Br3P
- IUPAC Name:
- phosphorus tribromide
- Test material form:
- liquid
- Details on test material:
- - Name of test material : Phosphorus tribromide
- Molecular formula: Br3P
- Molecular weight : 270.686 g/mol
- Smiles notation :P(Br)(Br)Br
- InChl :1S/Br3P/c14(2)3
- Substance type: Inorganic
- Physical state: Solid
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Phosphorus tribromide (phosphorus (3+) tribromide)
- Molecular formula (if other than submission substance): Br3P
- Molecular weight (if other than submission substance): 270.686 g/mol
- Substance type: Inorganic
- Physical state: Liquid
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Remarks:
- CDF®[F-344]/CrIBR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Age at study initiation: No data available
- Weight at study initiation: Males: 100-125g and Females- 75-100 g
- Fasting period before study: No fasting before study
- Housing: the animals (two per cage) were housed in laminar air flow rooms in clear plastic cages with hardwoodchip bedding
- Diet (e.g. ad libitum): Purina Certified Rodent Diet #5002 ad libitum except during the inhalation exposure period
- Water (e.g. ad libitum): Water ad libitum except during the inhalation exposure period and for 12 h prior to sacrifice for the 5-day study
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 to 25°C
- Humidity (%):No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): light/dark cycle was set at 12-h intervals
IN-LIFE DATES: From: To: No data available
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- nose only
- Vehicle:
- air
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Cannon chambers
- Method of holding animals in test chamber: Plexiglas restraining tubes with nose only chambers were used to hold the test animals
- Source and rate of air: Four Cannon nose-only inhalation chambers were supplied with dried laboratory air with a minimal air flow delivery rate of 500 mL/animal
- Method of conditioning air: No data
- System of generating particulates/aerosols: The required concentration of phosphorous tribromide was generated using Sage syringe pumps delivering the required mass of test material into the air supply for the Cannon-52 chambers.
- Temperature, humidity, pressure in air chamber: The temperature of the carrier air was monitored
- Air flow rate: 500 mL/min of dry (<3% RH) filtered house air with a minimum of 10 L/min used for each of the test groups
- Air change rate: No data available
- Method of particle size determination: No data available
- Treatment of exhaust air: A bypass and containment dump system was employed to allow for smooth initiation of exposures and for use as a safety measure in case of abnormal syringe pump operation. The containment areas were further isolated vfrom the general laboratory area through use of a separate exhaust line which vented the enclosures.
TEST ATMOSPHERE
- Brief description of analytical method used: A Bromide specific ion electrode permitted quantification of the test material concentration through analysis of the bromide ion absorbed in an ionic strength buffer (pH 4.0). In order to monitor the lower concentrations, the ratio of vapor sample to buffer had to be increased from 10:1 air/absorber to 20:1 and 40:1. This allowed operation in the linear portion of the response curve. Sixty-mL plastic syringes containing 5.0 mL buffer were used to quantify the 50 mL vapor samples and acted as the reaction vessel for the absorption of PBr3. Multiple absorption samples were required to analyze the lower chamber concentrations.
- Samples taken from breathing zone: No data available
VEHICLE (if applicable)
- Justification for use and choice of vehicle: Air
- Composition of vehicle: No data available
- Type and concentration of dispersant aid (if powder): No data available
- Concentration of test material in vehicle: 0, 0.05, 0.1, and 0.5 mg/L (Mean ± SD exposuer concentrations are 0.06 ± 0.01,0.16 ± 0.03, and 0.51 ± 0.08 mg/L)
- Lot/batch no. of vehicle (if required): No data available
- Purity of vehicle: No data available - Details on mating procedure:
- Reproductive organ were examined.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- A Bromide specific ion electrode permitted quantification of the test material concentration through analysis of the bromide ion absorbed in an ionic strength buffer (pH 4.0). In order to monitor the lower concentrations, the ratio of vapor sample to buffer had to be increased from 10:1 air/absorber to 20:1 and 40:1. This allowed operation in the linear portion of the response curve. Sixty-mL plastic syringes containing 5.0 mL buffer were used to quantify the 50 mL vapor samples and acted as the reaction vessel for the absorption of PBr3. Multiple absorption samples were required to analyze the lower chamber concentrations.
- Duration of treatment / exposure:
- 5 days
- Frequency of treatment:
- 4 hrs /day
Doses / concentrations
- Remarks:
- 0, 0.06, 0.16, 0.51 mg/L
- No. of animals per sex per dose:
- Total: 20
0 mg/L: 5 males
0.06 mg/L: 5 males
0.16 mg/L: 5 males
0.51 mg/L: 5 males - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The highest concentration of PBr3 was determined considering the results of the acute inhalation toxicity test
- Rationale for animal assignment (if not random): No data
- Rationale for selecting satellite groups: No data
- Post-exposure recovery period in satellite groups: No data
- Section schedule rationale (if not random): No data - Positive control:
- No data available
Examinations
- Parental animals: Observations and examinations:
- Mortality, Clinical signs, Body weight, Haematology and Clinical chemistry were examined.
- Oestrous cyclicity (parental animals):
- No data available
- Sperm parameters (parental animals):
- No data available
- Litter observations:
- No data available
- Postmortem examinations (parental animals):
- Organ weights, Gross pathology and Histopathology were examined.
- Postmortem examinations (offspring):
- No data available
- Statistics:
- Body weights were analyzed using the repeated mUltivariate analysis of variance with Scheffe pairwise comparisons. Hematology, clinical chemistry, and organ weights were analyzed using a two-factorial analysis of variance with multivariate comparisons. Histopathology data were analyzed through use of the Fischer Exact Test, or, if not valid, Yates' Corrected Chi-square was used.
- Reproductive indices:
- No data available
- Offspring viability indices:
- No data available
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, non-treatment-related
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- not specified
Details on results (P0)
Clinical signs: No signs of toxic stress were observed in treated male rats at 0.06, 0.16, 0.51 mg/L as compaed to control.
Body weight: When treated with 0.51 mg/L, significantly significant decrease in body weight was observed as compared to control.
Haematology: Statistically significant decrease in Basophils level were observed in 0.05 mg/L treated rats as compared to control.
Clinical chemistry:
Statistically significant increased in calcium, potassium, Chloride and Potassium values and Decrease in alkaline phosphatase, creatine and ALT kinase were observed as compared to control when treated with 0.51 mg/L.
Decrease in ALT and increase in Chloride values were observed as compared to control when treated with 0.16 mg/L.
Organ weights: No statistically significant effect on Absolute and relietive Liver, Kidneys, Testes, Brain, Spleen, Adrenals, Lungs, Thymus and Heart weight were observed in treated rats compared to control.
Gross pathology: When treated with 0.51 mg/L, irregular shaped and reddened nares in 3 male rats were observed.
When treated with 0.06 and 0.16 mg/L, no gross pathological changees were observed in treated male rats as compared to control.
Histopathology: When treated with 0.51 mg/L, lesions were observed in the anterior-most
segment of the nasal passages, statistically higher incidence of suppurative (acute) inflammation of the mucosa of the nasal passages, Chronic ulceration of the epithelium of the external nares was observed in 3 male and Minimal squamous metaplasia of the respiratory epithelium in the trachea of one male rat wereobserved as compared to control.
When treated with 0.16 mg/L, in one rat slight inflammation of the nasal mucosa (most anterior regions) were observed as compared to control.
When treated with 0.06 mg/L, no microscopic lesions were observed in treated male rats as compared to control.
Effect levels (P0)
- Dose descriptor:
- NOAEC
- Effect level:
- 0.51 mg/L air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- organ weights and organ / body weight ratios
- other: No effect on reproductive organ
Target system / organ toxicity (P0)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Results: P1 (second parental generation)
General toxicity (P1)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- not specified
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
Reproductive function / performance (P1)
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- not specified
Effect levels (P1)
- Dose descriptor:
- other: not specified
- Based on:
- not specified
- Sex:
- not specified
- Basis for effect level:
- other: not specified
- Remarks on result:
- other: not specified
Target system / organ toxicity (P1)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- not specified
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Other effects:
- not specified
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not specified
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not specified
Effect levels (F1)
- Dose descriptor:
- other: not specified
- Generation:
- other: not specified
- Based on:
- not specified
- Sex:
- not specified
- Basis for effect level:
- other: not specified
- Remarks on result:
- other: not specified
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not specified
- Mortality / viability:
- not specified
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Other effects:
- not specified
Developmental neurotoxicity (F2)
- Behaviour (functional findings):
- not specified
Developmental immunotoxicity (F2)
- Developmental immunotoxicity:
- not specified
Effect levels (F2)
- Dose descriptor:
- other: not specified
- Generation:
- other: not specified
- Based on:
- not specified
- Sex:
- not specified
- Basis for effect level:
- other: not specified
- Remarks on result:
- other: not specified
Target system / organ toxicity (F2)
- Critical effects observed:
- not specified
- System:
- other: not specified
- Organ:
- not specified
- Treatment related:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
- Treatment related:
- not specified
- Relation to other toxic effects:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Any other information on results incl. tables
Organ Weights and Organ-To-Bodyweight Ratios Of Male F-344 Rats After Five-Day, Nose-Only Inhalation Exposure To Phosphorus Tribromide
Organ |
Control |
0.05 mg/L |
0.1 mg/L |
0.5 mg/L |
Body Wt |
226 ± 8.6 |
225 ± 8.6 |
221 ± 10.6 |
214 ± 7.9 |
Liver |
7.12 ± 0.72 |
6.88 ± 0.57 |
6.65 ± 0.37 |
6.47 ± 0.56 |
Kidneys |
1.77 ± 0.08 |
1.76 ± 0.08 |
1.52 ± 0.41 |
1.68 ± 0.08 |
Testes |
2.84 ± 0.13 |
2.78 ± 0.09 |
2.53 ± 0.46 |
2.65 ± 0.12 |
Brain |
1.79 ± <0.01 |
1.79 ± 0.04 |
1.78 ± 0.01 |
1.74 ± 0.06 |
Adrenals |
0.04 ± 0.02 |
0.05 ± 0.01 |
0.05 ± 0.01 |
0.05 ± 0.01 |
Lungs |
1.45 ± 0.14 |
1.34 ± 0.10 |
1.46 ± 0.07 |
1.09 ± 0.61 |
Thymus |
0.25 ± 0.04 |
0.22 ± 0.03 |
0.20 ± 0.03 |
0.19 ± 0.02 |
Heart |
0.79 ± 0.04 |
0.81 ± 0.05 |
0.81 ± 0.02 |
0.82 ± 0.06 |
a Mean ± SO, N=5.
b Organ weight/body weight x 100.
Applicant's summary and conclusion
- Conclusions:
- NOAEC was considered to be 0.51 mg/l when Fischer 344 (F-344) CDF®[F-344]/CrIBR male rats were treated with phosphorus (3+) tribromide by Nose only vapor inhalation for 4 hrs /day for 5 days.
- Executive summary:
In a Subacute inhalation toxicity study, Fischer 344 (F-344) CDF®[F-344]/CrIBR male rats were treated with phosphorus (3+) tribromide in the concentration of 0, 0.06,0.16, 0.51 mg/L by Nose only vapor inhalation for4 hrs /day for 5 days. No mortality and signs of toxic stress were observed in treated male rats at 0.06, 0.16, 0.51 mg/L as compared to control. Significantly significant decrease in body weight was observed in0.51 mg/L treated male rats as compared to control. Similarly, Statistically significant decrease in Basophils level were observed in 0.05 mg/L and Statistically significant increased in calcium, potassium, Chloride and Potassium values and Decrease in alkaline phosphatase, creatine and ALT kinase were observed at 0.51 mg/L and Decrease in ALT and increase in Chloride values were observed as compared to control when treated with 0.16 mg/L. Additional statistically significant differences in mean values of serum chemistry or hematologic parameters were sporadic and were not considered biologically important. In addition, No statistically significant effect on Absolute and relietive Liver, Kidneys, Testes, Brain, Spleen, Adrenals, Lungs, Thymus and Heart weight were observed in treated rats compared to control. Irregular shaped and reddened nares in 3 male rats were observed at 0.51 mg/L and no gross pathological changes were observed in treated male rats at 0.06 and 0.16 mg/L as compared to control. Lesions were observed in the anterior-most segment of the nasal passages, statistically higher incidence of suppurative (acute) inflammation of the mucosa of the nasal passages, Chronic ulceration of the epithelium of the external nares was observed in 3 male and Minimal squamous metaplasia of the respiratory epithelium in the trachea of one male rat were observed at 0.51 mg/L as compared to control. In one rat slight inflammation of the nasal mucosa (most anterior regions) were observed at 0.16 mg/L as compared to control andno microscopic lesions were observed in treated male rats at0.06 mg/L as compared to control. Therefore, NOAEC was considered to be 0.51 mg/l when Fischer 344 (F-344) CDF®[F-344]/CrIBR male rats were treated with phosphorus (3+) tribromide by Nose only vapor inhalation for4 hrs /day for 5 days..
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.